Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

被引：5

作者：

Finn, Richard S.

Chan, Stephen L.

Zhu, Andrew X.

Knox, Jennifer J.

Cheng, Ann-Lii

Siegel, Abby B.

Bautista, Oliver

Kudo, Masatoshi

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Prince Wales Hosp, Shatin, Hong Kong, Peoples R China

[3] Massachusetts Gen Hosp, Boston, MA 02114 USA

[4] Princess Margaret Canc Ctr, Toronto, ON, Canada

[5] Univ Toronto, Toronto, ON, Canada

[6] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[7] Merck & Co Inc, Kenilworth, NJ USA

[8] Kindai Univ, Fac Med, Osaka, Japan

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS4143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4143

引用

页数：6